Clinical trials: Psoriasis; Plaque
Genital Psoriasis, Scalp Psoriasis
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- UnlIMMited (NCT05969223)
- Testing
- Risankizumab
- Where
- 38 sites in United States
- Volunteers
- 214 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease
- Trial name
- Adherence (NCT01768858)
- Testing
- Adalimumab
- Volunteers
- 96 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the…
- Trial name
- NCT02310750
- Testing
- PF-06700841 oral solution/suspension, PF-06700841 tablet
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Plaque Psoriasis
Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis
The study will evaluate the efficacy of cyclosporine at 2, 5 mg/kg/day bid (i.e. bis in a day), when administered twice a week compared to continuous administration, in patients with chronic plaque psoriasis.
- Trial name
- NCT00438360
- Testing
- Cyclosporine A microemulsion
- Where
- Italy
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies
The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.
- Trial name
- NCT00689481
- Testing
- U0267 Foam, Vehicle foam
- Where
- 12 sites in United States
- Volunteers
- 323 people
- Sponsor
- Stiefel, a GSK Company
Plaque Psoriasis
Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test
Evaluation of safety, pharmacokinetics, and anti-psoriatic efficacy to assess SOR007 Ointment in topical formulations
- Trial name
- NCT03004339
- Testing
- SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- DFB Soria, LLC
Psoriasis Vulgaris
A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris
The purpose of this study is to evaluate the anti-psoriatic effect of LEO 27989 ointment and calcipotriol plus LEO 27989 ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
- Trial name
- NCT01297166
- Testing
- LEO 27989 ointment, Calcipotriol plus LEO 27989 ointment, Calcipotriol ointment
- Where
- France
- Volunteers
- 25 people
- Sponsor
- LEO Pharma
Psoriasis
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.
- Trial name
- NCT00692172
- Testing
- Alefacept
- Where
- 43 sites in United States, Belgium and 7 more
- Volunteers
- 175 people
- Sponsor
- Astellas Pharma Inc
Plaque Psoriasis
A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis.
- Trial name
- AFFIRM-35 (NCT03591887)
- Testing
- ABY-035
- Where
- 18 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Affibody
Psoriasis, Arthritis, Psoriatic
MYL-1401A Efficacy and Safety Comparability Study to Humira®
To assess the equivalence of MYL-1401A to Humira® with regards to efficacy in subjects with moderate-to-severe chronic plaque psoriasis
- Trial name
- NCT02714322
- Testing
- MYL-1401A (Adalimumab), Humira® (Adalimumab)
- Where
- 33 sites in Bulgaria, Estonia and 4 more
- Volunteers
- 294 people
- Sponsor
- Mylan Inc.
Chronic Small Plaque Psoriasis
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
The primary objective of the study is to evaluate the safety and tolerability of 50, 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with plaque psoriasis
- Trial name
- NCT00396422
- Testing
- RWJ-445380
- Volunteers
- 60 people
- Sponsor
- Alza Corporation, DE, USA
Psoriasis
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male…
- Trial name
- SPECIFI-PSO (NCT06073119)
- Testing
- SAR441566
- Where
- 51 sites in United States, Argentina and 15 more
- Volunteers
- 221 people
- Sponsor
- Sanofi
Moderate Plaque Psoriasis
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen).
- Trial name
- IMMpactful (NCT06333860)
- Testing
- Risankizumab, Deucravacitinib
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 393 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis
This study is a randomized, double-blind, multicenter, dose-parallel-controlled phase II clinical trial. The study consists of three stages: a 4-week screening period, a 52-week treatment period, and a 12-week follow-up period.
- Trial name
- NCT07758075
- Testing
- SHR-1139, SHR-1139 and SHR-1139 pleacebo
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Psoriasis
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT04673786
- Testing
- CT-P43, Stelara
- Where
- Estonia
- Volunteers
- 509 people
- Sponsor
- Celltrion
Scalp Psoriasis
Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis
The study will be conducted to evaluate the efficacy and safety of a topical dimeticone formulation (Loion®) compared to 10% salicylic acid in octyl-dodecanol with 15% Macrogol-4-laurylether for the removal of scaling in patients…
- Trial name
- NCT01914627
- Testing
- Dimethicone, Salicylic Acid
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- G. Pohl-Boskamp GmbH & Co. KG
Psoriasis
Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07707141
- Testing
- HPP737 20mg
- Where
- 8 sites in China
- Volunteers
- 123 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Moderate to Severe Chronic Plaque Psoriasis
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate…
- Trial name
- AbGn-168H (NCT01855880)
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
- Trial name
- BE ABLE 2 (NCT03010527)
- Testing
- Bimekizumab
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 217 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Adalimumab in Adult Japanese Subjects With Psoriasis
To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis
- Trial name
- NCT00647400
- Testing
- adalimumab
- Where
- 64 sites in Japan
- Volunteers
- 147 people
- Sponsor
- Abbott